Can a cancer drug make stem cell transplants safer for myelofibrosis patients?

NCT ID NCT04384692

Ongoing Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving the drug ruxolitinib before, during, and after a donor stem cell transplant can prevent graft-versus-host disease (GVHD) in people with myelofibrosis. GVHD is a serious complication where donor cells attack the patient's body. The trial enrolls 53 adults with intermediate- or high-risk myelofibrosis. Ruxolitinib is already used to reduce symptoms like enlarged spleen and night sweats, and researchers hope it will also lower GVHD risk and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ruxolitinib
What this could lead to: If successful, this approach could reduce severe graft-versus-host disease and improve survival and quality of life for myelofibrosis patients undergoing stem cell transplant.
What could go wrong: This is a small, early-phase (Phase 2) trial with only 53 participants, so results may not apply broadly. Ruxolitinib can cause side effects like infections or blood count changes, and the transplant itself carries serious risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY MYELOFIBROSIS SECONDARY MYELOFIBROSIS

Contacts and locations

Locations

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.